PropeciaPrice.com - Estimating the R&D Costs of Successful Products

To estimate the R&D costs of of the successful products, which are the length and the complexity of the R&D of process, which R&D are estimating given to total costs of a successful pharmaceutical product, a frightening methodologische challenge, which therefore a source of the controversy remained, evenly among economists. For there is to attribute the question, which to a certain, to successful product costs. A research-created pharmaceutical company can be compared to an oil company, the world on the search for oil deposits roamed across. Such a company bores many drillings, which finally do not furnish oil can. The costs these dry drillings to be thenmust brought by the successful wells. Therefore the costs of the dry drillings are assigned to the costs by routine of successfulwells. It is, therefore alsowith pharmaceutical must be added companies.To, which took itself totalR&Dcost directly for successful new products, the R&D costs of the products, which will leave process somewhere along the long-winded R&D had. Forming this cost writing up represents correctly the first methodologische challenge, if it estimates the R&D costs of the new drugs. Asecondmethodological problem is howto convertmonetary expenditures for R&D, those over the overvoltage of an entire decade to be formed or more in individual 32 Uwe E. Reinhardt quantity, which is stopped correctly to inflation and the money current value. Even after adjustment only represents $1 million much spent on inflation, which is direct, today more value than $1 a decade therefore to be spent million, because many less than $1 million now therefore would have to be invested, in order to have in the hand $1 million decade. The financial closed expenditures over time therefore are converted into a number with identical current value, either starting from the at the beginning of the time-divided circulation of money, the so-called present value of the circulation of money or at its end, the so-called terminal value of the circulation of money. Transformation in present or terminal values with interest rate formed, which the pharmaceutical loaded average annual costs of the enterprise of debt and of share capital, which weights reflected, which are used the relative breaks of the debt and the cheapness, are to be raised, around outside financing. The interest rates, which are used for this purpose, reflect the outside costs of the investors of the investment of their money in the enterprise, instead of in any riskless value e.g. a long-term government loan, plus a Riskiopraemie, to the investors for the danger to adjust accept it, by investing with this certain enterprise. The fact that over a given time-divided flow CAN cash is advised either into its present, or terminal value the persons easily to confuse can do, who are familiar with national economy or finance.Toillustratewith stylized an example, takes that relevantR& the Doutlays for aproduct representanevenmoneyflowof announces we $50 million one year for 10 years. If the loaded average price of the enterprise of financing we say 10% per year were, then have this cash flowwould a present value of $307 million starting from the beginning this money flow and a terminal value of $797 million at its terminator point to discharge supposed, if the product is in, into the market. At a loaded average price financing of we say 8%, the two values $335 million and $724 million, and/or would be. At loaded costs financing of 15%, they would be $251 million and $1,015 million, and/or. All represent these different illustrations an identical circulation of money nevertheless. One can think of the present value of the R&D of river, how the sum of the money, which firmwould on the deposit have must to finance to the 10jaehrigen of river of the R&D expenditure of $50 million one year if the balance in the account could acquire the loaded average price of the enterprise of the financing per year. The terminal value the total quantity of the money, which invested the enterprise in the R&D project in the name of the shareholders for the date of the product introduction, became alternate including which represent accumulated interest, that the loaded costs of the enterprise of financing, which is equal return the enterprise on alternative projects have probably acquired could. Which of these numbers is the most attached, depends on the use, to which it is set. For practical purposes is the terminal value probably more intuitively pleases, because at the time of the product introduction of the pharmaceutical sector in the new pharmaceutical product the health care 33, it the quantity, which the present value of all future sales profits of the product, minus which production, marketing and other future annual costs with the sales of the product connected, which must be covered enterprises is. ErWAR worth to enter into this methodologische detail over the estimation of R&D costs because general estimations of those costs bend to be so disputed. DiMasi, Hansen and Grabowski (2003) estimated recently the costs of United States pharmaceutical enterprises on between $800 million and $900 million. These estimations were tackled immediately, as exaggerated by Light and Warburton (2005) in the same journal. Such arguments could develop for surplus somehow or all following expenditures: (1) used the estimations of the actual R&D expenditures, those to be attributed correctly should for a successful product, (2) the interest rate to calculate the present or terminal value of this circulation of money and (3) whether, for the politics policies, which is present or terminal value of this circulation of money the more suitable illustration. In the end the only approximation to agreeing upon such debates should form the raw data, which were used if her such estimations accessible for each possible researcher, made, which would like to revise the computations (Reinhardt 1997). However those expenditures are agreed upon, there cannot be a doubt to discharge that upfront R&D costs, which are taken, in order a new pharmaceutical product in the hundreds of millions dollar, not only in the United States is, but other where in addition.